ÖÐÎÄÃû³Æ£º Íÿ¹NAPSA¶à¿Ë¡¿¹Ìå
Ó¢ÎÄÃû³Æ£º Anti-NAPSA rabbit polyclonal antibody
±ð Ãû£º KAP; Kdap; NAP1; NAPA; SNAPA
Ïà¹ØÀà±ð£º Ò»¿¹
´¢ ´æ£º Àä¶³£¨-20¡æ£©
¿¹ Ô£º NAPSA
ËÞ Ö÷£º Rabbit
·´Ó¦ÖÖÊô£º Human, Mouse
±ê ¼Ç Î Unconjugate
¿Ë¡ÀàÐÍ£º rabbit polyclonal
¼¼Êõ¹æ¸ñ
|
Background: |
The activation peptides of aspartic proteinases plays role as inhibitors of the active site. These peptide segments, or pro-parts, are deemed important for correct folding, targeting, and control of the activation of aspartic proteinase zymogens. The pronapsin A gene is expressed predominantly in lung and kidney. Its translation product is predicted to be a fully functional, glycosylated aspartic proteinase precursor containing an RGD motif and an additional 18 residues at its C-terminus. |
|
Applications: |
ELISA, WB, IHC |
|
Name of antibody: |
NAPSA |
|
Immunogen: |
Fusion protein of human NAPSA |
|
Full name: |
napsin A aspartic peptidase |
|
Synonyms£º |
KAP; Kdap; NAP1; NAPA; SNAPA |
|
SwissProt: |
O96009 |
|
ELISA Recommended dilution: |
1000-5000 |
|
IHC positive control: |
Human liver cancer and Human gastric cancer |
|
IHC Recommend dilution: |
50-200 |
|
WB Predicted band size: |
45 kDa |
|
WB Positive control: |
mouse kidney tissue |
|
WB Recommended dilution: |
500-2000 |


¹ºÎï³µ
°ïÖú
021-54845833/15800441009
